EDGAR·FLOW

Monte Rosa Therapeutics, Inc. — Form 8-K

Filed November 5, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Monte Rosa announced positive GFORCE-1 Phase 1 results for MRT-8102 showing 80–90% NEK7 degradation and reduction in inflammatory markers comparable to healthy volunteers across all three doses, with safety profile similar to placebo. Novartis triggered two milestone payments totaling $87.5M ($50M for Sjögren's disease Phase 2 initiation, $37.5M for psoriatic arthritis Phase 2 initiation). Cash position stands at $582.6M as of September 30, 2026, expected to support operations into 2029.
Why this rating

Milestones represent 41% of company market cap; positive Phase 1 validates platform. Runway to 2029 is secure; clinical momentum across multiple programs is material for clinical-stage biotech.

Tradability signal
NO TRADE

No trade: positive news with only +1.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.53% over 4 hrs, n=325). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$10.50
+10 min · unknown
$10.41 ▼ 0.90%
+30 min · unknown
$10.50 ▲ 0.00%
+1 hr · unknown
$10.54 ▲ 0.43%
+4 hrs · unknown
$10.29 ▼ 2.05%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ GLUE · stock on Yahoo Finance ↗

See more from November 5, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.